TG Therapeutics Inc

2026. g. 17. sept. 19:54 UTC

TG Therapeutics Inc is moving higher as economic data shows unexpected labor market strength, despite a decline in housing starts.

2026. g. 16. sept. 23:56 UTC

TG Therapeutics Inc is trading lower in after-market hours, retracing from an initial high shortly after the market closed, despite remaining above its 20-day moving average.

2026. g. 15. sept. 23:41 UTC

TG Therapeutics shares are lower in after-market trading amid negative market sentiment. The New York Empire State Manufacturing Index fell sharply, raising investor caution.

2026. g. 14. sept. 19:16 UTC

TG Therapeutics Inc shares are lower today amid broader market declines. CEO Weiss highlighted upcoming catalysts, including a significant treatment administration method.

2026. g. 11. sept. 20:08 UTC

TG Therapeutics shares are declining during Friday's session, despite social media optimism about its subcutaneous BRIUMVI formulation and potential Priority Review Voucher benefits.

2026. g. 10. sept. 20:31 UTC

TG Therapeutics Inc shares are lower in after-market trading, reflecting a decline despite starting the session near the top of their one-month range.

2026. g. 9. sept. 20:07 UTC

TG Therapeutics shares are lower today amid cautious outlook from CEO Weiss and mixed analyst sentiment on sales estimates. Earlier, the stock pulled back from session highs.

2026. g. 4. sept. 20:07 UTC

TG Therapeutics Inc is declining amid increased selling pressure in risk assets following a strong jobs report raising monetary policy concerns.

2026. g. 3. sept. 20:07 UTC

TG Therapeutics will participate in the Cantor Global Healthcare Conference. Shares are lower today, despite earlier gains and positive sentiment surrounding the company.

2026. g. 2. sept. 20:02 UTC

TG Therapeutics shares are higher as HC Wainwright reiterates its Buy rating. Social media valuations suggest a price range of $78 to $85 per share.

2026. g. 1. sept. 19:54 UTC

TG Therapeutics shares are rising as H.C. Wainwright maintains a Buy rating and sets a price target of $78, indicating significant upside potential.

2026. g. 31. aug. 22:16 UTC

TG Therapeutics Inc. shares showed little change in after-market trading. The stock remains above its 20-day moving average, indicating stability.

2026. g. 28. aug. 19:51 UTC

TG Therapeutics Inc shares are lower today, continuing a decline since Thursday's close. The stock remains above its 20-day moving average.

2026. g. 27. aug. 23:41 UTC

TG Therapeutics Inc shares are lower in after-market hours, reflecting broader market declines. Economic indicators have not alleviated cautious sentiment amid inflation concerns.

2026. g. 26. aug. 19:16 UTC

TG Therapeutics raised its Briumvi revenue guidance to $890-$905 million, contributing to an upgrade of TGTX stock. Shares are trading roughly flat today.

2026. g. 25. aug. 23:36 UTC

TG Therapeutics Inc. shares are trading roughly flat in after-market hours. The stock remains above its 20-day moving average and near its one-month trading range.

2026. g. 24. aug. 23:21 UTC

TG Therapeutics Inc shares are higher in after-market hours, reflecting positive momentum following Monday's close, despite no specific news driving the movement.

2026. g. 22. aug. 00:02 UTC

TG Therapeutics shares are higher in after-market trading amid positive investor sentiment and discussions of significant price targets of $150 following recent market pressures.

2026. g. 21. aug. 23:01 UTC

TG Therapeutics Inc. is rising in after-market trading, fueled by positive investor sentiment and potential price targets between $150 and $200.

2026. g. 20. aug. 21:01 UTC

TG Therapeutics Inc shares are higher in after-market hours, despite earlier declines. No specific news was identified to explain the price movement.

2026. g. 19. aug. 19:27 UTC

TG Therapeutics Inc shares are higher today, continuing an upward trend since Tuesday. The stock is trading above its 20-day moving average.

2026. g. 17. aug. 19:56 UTC

TG Therapeutics reported Q2 2026 revenue of $240.34 million and raised its full-year outlook to $950 million, driving shares higher during Monday's trading.

2026. g. 14. aug. 21:01 UTC

TG Therapeutics Inc shares are lower in after-market trading amid broader market weakness. Disappointing U.S. retail sales data may be impacting investor sentiment.

2026. g. 13. aug. 20:02 UTC

TG Therapeutics Inc shares declined during Thursday's session, influenced by social media sentiment and prior bearish commentary from Bank of America.

2026. g. 10. aug. 19:16 UTC

TG Therapeutics Inc shares are lower today amid a broader market decline, with U.S. stock futures dropping following a surprising labor market report.

2026. g. 7. aug. 23:16 UTC

TG Therapeutics Inc shares are lower in after-market trading. No specific news was identified to explain the movement, which may reflect broader market sentiment.

2026. g. 6. aug. 20:03 UTC

TG Therapeutics is lower today, impacted by declines in the Biotechnology sector. The company reported higher revenue but noted a decrease in net income and EPS.

2026. g. 5. aug. 19:56 UTC

TG Therapeutics is higher as analysts project GAAP net income could exceed $350 million in 2027, driven by revenue growth and pipeline developments.

2026. g. 4. aug. 23:56 UTC

TG Therapeutics Inc. shares are roughly flat in after-market trading. The price remains below its 20-day moving average, indicating ongoing weakness.

2026. g. 3. aug. 23:06 UTC

TG Therapeutics Inc. shares are higher in after-market trading following Q2 revenues of $236 million and ongoing positive sentiment from clinical trials.